Drug intelligence / Profile preview

3511-I

Development stage: Preclinical
Modality: Small Molecules

Overview

3511-I is a novel small-molecule inhibitor targeting EphB2 (Ephrin type-B receptor 2). Preclinical studies in a mouse model of unilateral renal ischemia-reperfusion (IR) injury demonstrated that treatment with 3511-I significantly attenuated kidney injury and fibrosis. Its mechanism involves promoting tubular repair and suppressing sustained inflammatory signaling, similar to the effects observed with tubular-specific genetic deletion of EphB2.

Targets

EPHB2 (Ephrin type-B receptor 2)

Beyond the preview

Go deeper on 3511-I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3511-I.

Explore the full profile